Delivery Order SPE2DB22D3501-SPE2DB25FXK68
- Not listed
- The Defense Logistics Agency awarded a $11,057.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply), with an ultimate completion date of September 11, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is...
- The Defense Logistics Agency awarded a $19,211.98 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging) under a firm fixed price contract. The award was made competitively with no set-aside designation on April 24, 2025, with completion expected by April 25, 2025. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $10,286.15 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed-price delivery order with an ultimate completion date of September 9, 2025, issued under a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. The award represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $7,474.25 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on August 14, 2025, with completion targeted for August 15, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical procurement under the company's existing indefinite delivery vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a $17,662.48 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count package) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitive, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) under a firm fixed-price contract valued at $13,195.78. The award, issued on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a non-set-aside competitive award. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency awarded a $15,645.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30 count) on September 15, 2025, with completion expected by September 16, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $2,425.07 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply). This competitively awarded, firm fixed-price delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025, and represents a non-set-aside procurement. The work is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $12,168.39 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This contract employs firm fixed pricing and was competitively awarded without set-aside provisions. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXK68Delivery Order
The Defense Logistics Agency awarded a $39,771.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 MG tablets (30-count units) under a firm fixed price contract type. The award, issued on September 18, 2025, with an ultimate completion date of September 19, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value through December 2026. This prime indefinite delivery vehicle enables the contractor to supply comprehensive pharmaceutical products and medical supplies globally to support military healthcare programs. The current award for ondansetron—an anti-nausea medication commonly used in medical settings—reflects the company's ongoing role in fulfilling DLA's pharmaceutical supply requirements across multiple therapeutic domains for the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.8k | 9/18/25 |